CAM
IBIO icon

Cormorant Asset Management’s iBio IBIO Stock Holding History

Cormorant Asset Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.25M Buy
+3,570,000
New +$6.38M 0.32% 38

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Cormorant Asset Management's IBIO Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in iBio (IBIO) in Q2 2026: 3,570,000 shares worth $6.25M. The stake represents 0.32% of the portfolio and ranks #38 among its holdings.

51 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Cormorant Asset Management held 3,570,000 shares of iBio worth $6.25M as of Q2 2026.
  • iBio was a new Cormorant Asset Management position in Q2 2026.
  • iBio made up 0.32% of Cormorant Asset Management's portfolio in Q2 2026, its #38 holding.
  • 51 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.